Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

Protease selectivity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ClpP (6) HCV Protease (20) HIV Protease (28) Protease Activated Receptor (PAR) (29) Ser/Thr Protease (10) Serpin (1) TMPRSS6 (1) Virus Protease (16) Angiotensin-converting Enzyme (ACE) (1) APC (2) Apoptosis (23) Atg4 (1) Autophagy (2) Bacterial (10) Beta-lactamase (1) Beta-secretase (2) Cadherin (1) Cathepsin (12) CDK (1) Cholecystokinin Receptor (1) Complement System (3) Cytochrome P450 (10) Dengue Virus (3) Deubiquitinase (14) Drug Metabolite (1) EGFR (1) Elastase (1) Endogenous Metabolite (13) Enterovirus (3) ERK (1) Factor VIII (1) Factor Xa (16) Factor XI (1) FAK (1) FAP (2) Flavivirus (2) Fluorescent Dye (1) Free Fatty Acid Receptor (2) Fungal (1) Furin (2) Glucocorticoid Receptor (2) HCV (14) HIV (30) IKK (1) Isotope-Labeled Compounds (14) JAK (3) Kallikrein (1) MALT1 (4) MDM-2/p53 (2) Mitochondrial Metabolism (4) Mitophagy (2) MMP (5) NF-κB (2) P-glycoprotein (8) Parasite (2) Potassium Channel (2) PROTACs (3) Proteasome (7) Reference Standards (17) Reverse Transcriptase (1) SARS-CoV (50) SDCBP (1) Syk (1) Thrombin (9) Toll-like Receptor (TLR) (3) TREM receptor (1) TRP Channel (2) β-catenin (1) γ-secretase (1)
By Research Areas:	Cancer (61) Cardiovascular Disease (43) Endocrinology (1) Infection (98) Inflammation/Immunology (28) Metabolic Disease (11) Neurological Disease (19)
Click Chemistry:	Alkynes (1)

208

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Virus Protease HCV Protease HIV Protease Protease Activated Receptor (PAR) ClpP TMPRSS6 Calpain Serpin Enteropeptidase Ser/Thr Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15667

P005091 20+ Cited Publications P5091	Deubiquitinase	Cancer
P005091 is a selective and potent inhibitor of *ubiquitin-specific protease* 7 (USP7) with an EC₅₀** of 4.2 μM.

HY-P0078

TRAP-6 5+ Cited Publications PAR-1 agonist peptide; Thrombin Receptor Activator Peptide 6	Protease Activated Receptor (PAR)	Inflammation/Immunology
TRAP-6 (PAR-1 agonist peptide), a peptide fragment, is a selective protease activating receptor 1 (PAR1) agonist. TRAP-6 activates human platelets via the thrombin receptor. TRAP-6 shows no activity at PAR4 .

HY-108462

ML-SA1 5+ Cited Publications	Dengue Virus TRP Channel Flavivirus	Infection
ML-SA1, as a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC₅₀ value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively. ML-SA1 induces autophagy. ML-SA1 can be used for the research of broad-spectrum antiviral .

HY-10235

Telaprevir 40+ Cited Publications VX-950	HCV Protease HCV SARS-CoV	Infection
Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (K_i) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-14588

Lopinavir 15+ Cited Publications ABT-378	HIV HIV Protease SARS-CoV	Infection Neurological Disease Cancer
Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-18236

MDL-28170 15+ Cited Publications Calpain Inhibitor III	Proteasome	Neurological Disease Inflammation/Immunology
MDL-28170 (Calpain Inhibitor III) is a potent, selective and membrane-permeable cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration . MDL-28170 also block γ-secretase .

HY-10264

Edoxaban 5+ Cited Publications DU-176	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .

HY-117793

I-191 1 Publications Verification	Protease Activated Receptor (PAR)	Cancer
I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonist .

HY-139399

Safimaltib 2 Publications Verification JNJ-67856633	MALT1	Cancer
Safimaltib (JNJ-67856633) is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. Safimaltib in some cases lead to tumor stasis .

HY-153045

BAY-805 3 Publications Verification	Deubiquitinase	Cancer
BAY-805, a chemical probe, is a selective inhibitor of ubiquitin-specific protease USP21. BAY-805 has high selectivity for deubiquitinating enzyme (DUB) targets, kinases, proteases and other common target enzymes .

HY-116815

Lalistat 1 2 Publications Verification	Beta-lactamase Bacterial	Infection Neurological Disease
Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC₅₀ of 68 nM. Lalistat 1 is a inhibitor of *immunoglobulin A1 protease* (IgA1P)** proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .

HY-10264B

Edoxaban tosylate monohydrate 5+ Cited Publications DU-176b monohydrate	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .

HY-10264A

Edoxaban tosylate 5+ Cited Publications DU-176b	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .

HY-121282

Mepazine 2 Publications Verification Pecazine	MALT1 Apoptosis	Cancer
Mepazine (Pecazine) is a potent and selective MALT1 protease inhibitor with IC₅₀s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine affects viability of ABC-DLBCL cells by enhancing apoptosis .

HY-19837

BMS-986120 1 Publications Verification	Protease Activated Receptor (PAR)	Inflammation/Immunology
BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 (PAR4) antagonist, with IC₅₀s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects .

HY-125959

Ucf-101 1 Publications Verification	Apoptosis	Cardiovascular Disease Neurological Disease
Ucf-101 is a selective and competitive inhibitor of *pro-apoptotic protease* Omi/HtrA2, with an IC₅₀ of 9.5 μM for His-Omi*. Ucf-101 exhibits very little activity against various other serine proteases* (IC₅₀>200 μM). Ucf-101 has a natural red fluorescence at 543 nm that is used to monitor its ability to enter mammalian cells. Ucf-101 has a significant cardioprotective effect against MI/R injury and also has certain neuroprotective effect .

HY-128971

LHVS 3 Publications Verification	Cathepsin Parasite	Infection Neurological Disease
LHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC₅₀ of 10 μM .

HY-13487

USP7/USP47 inhibitor 3 Publications Verification	Deubiquitinase	Cancer
USP7/USP47 inhibitor is a selective *ubiquitin-specific protease* 7/47 (USP7/USP47) inhibitor, with EC₅₀**s of 0.42 μM and 1.0 μM, respectively.

HY-122700

Factor D inhibitor 6	Complement System	Inflammation/Immunology
Factor D inhibitor 6 is a potent, highly selective and orally active factor D (FD) inhibitor with an IC₅₀ of 30 nM and a K_d of 6 nM. Factor D inhibitor 6 is inactive against factor B, lassical and lectin complement-pathway activation, and a broad assay panel of receptors, ion channels, kinases and proteases .

HY-P2518

Protease-Activated Receptor-1, PAR-1 Agonist	Protease Activated Receptor (PAR)	Inflammation/Immunology
Protease-Activated Receptor-1, PAR-1 Agonist is a selective proteinase-activated receptor1 (PAR-1) agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor .

HY-10300

Narlaprevir 5 Publications Verification SCH 900518	HCV HCV Protease SARS-CoV	Infection
Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a K_i value of 6 nM and an EC₉₀ value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.3 μM .

HY-16709

USP7-IN-1 5+ Cited Publications	Deubiquitinase	Cancer
USP7-IN-1 is a selective and reversible inhibitor of *ubiquitin-specific protease* 7 (USP7), with an IC₅₀** of 77 μM, and can be used for the research of cancer.

HY-P4284

Z-GGF-CMK	Proteasome ClpP Bacterial	Infection
Z-GGF-CMK is an Antibacterial agent, an inhibitor of the ClpP1P2 serine protease complex (with an IC₅₀ of 50 μM against intracellular ClpP1P2 protease activity in Mycobacterium bovis BCG), and a selective inhibitor of the mycobacterial Proteasome (with an IC₅₀ of 50 μM against the proteasome in M. bovis BCG). Z-GGF-CMK inhibits the growth of mycobacteria. Z-GGF-CMK exhibits cytotoxic activity against liver cancer cells. Z-GGF-CMK can be used in the research of tuberculosis .

HY-18200

Atopaxar E5555; ER-172594-00	Protease Activated Receptor (PAR) JAK Apoptosis	Cardiovascular Disease Cancer
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease .

HY-121282A

Mepazine hydrochloride 2 Publications Verification Pecazine hydrochloride	MALT1 Apoptosis	Cancer
Mepazine hydrochloride (Pecazine hydrochloride) is a potent and selective MALT1 protease inhibitor with IC₅₀s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine hydrochloride affects viability of ABC-DLBCL cells by enhancing apoptosis .

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .

HY-14351

AC-264613	Protease Activated Receptor (PAR)	Inflammation/Immunology
AC-264613 is a potent and selective protease-activated receptor (PAR-2) agonist with a pEC₅₀ of 7.5 .

HY-112818

S130	Atg4 Cathepsin Autophagy Apoptosis	Cancer
S130 is a high affinity, selective inhibitor of ATG4B (a major cysteine protease) with an IC₅₀ of 3.24 µM. S130 suppresses autophagy flux .

HY-152101

LY1	SARS-CoV	Infection
LY1 is a potent, selective and covalent inhibitor against both SARS-CoV-2 PL ^pro and M ^pro with K_d values of 1.5 μM and 2.3 μM for M ^pro C145A protein and PL ^pro C111A protein, respectively. LY1 potent against the viral proteases, with IC₅₀s of 0.12 μM and 0.99 μM against M ^pro and PL ^pro. LY1 shows high selectivity over other kinases, human proteases and metalloenzyme .

HY-150790

BMS-986141	Protease Activated Receptor (PAR)	Cardiovascular Disease
BMS-98614 is an orally active, selective thrombin receptor protease-activated receptor-4 (PAR-4) antagonist with an IC₅₀ value of 0.4 nM. BMS-98614 has excellent antithrombotic effect .

HY-148072

MM3122	SARS-CoV	Infection
MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC₅₀ value of 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells .

HY-163319

NCA029	ClpP Apoptosis	Cancer
NCA029 is a potent and selective *homo sapiens caseinolytic protease* P (HsClpP) activator with an EC₅₀** of 0.15 μM. NCA029 acts on HsClpP to activate an ATF3-dependent integrative stress response, leading to colon cancer cell death .

HY-120528A

GB-110 hydrochloride 1 Publications Verification	Protease Activated Receptor (PAR)	Inflammation/Immunology Cancer
GB-110 hydrochloride is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist. GB-110 hydrochloride selectively induces PAR2-mediated intracellular Ca ²⁺ release in HT29 cells with an EC₅₀ of 0.28 μM .

HY-W790014

Z-FG-NHO-BzOME	Cathepsin	Infection
Z-FG-NHO-BzOME is a cysteine protease inhibitor that selectively inhibits cathepsin B, cathepsin L, cathepsin S, and papain .

HY-19400

DPC-681 DPH-153893	HIV Protease HIV	Infection
DPC-681 is a potent and selective inhibitor of HIV protease with IC90s for wild-type HIV-1 of 4 to 40 nM.

HY-Y0241

2-Cyanopyrimidine	Cathepsin	Metabolic Disease
2-Cyanopyrimidine is a potent and non-selective *cysteine protease* cathepsin K inhibitor with an IC₅₀** of 170 nM. 2-Cyanopyrimidine is used for osteoporos .

HY-112968

Human protein C	APC	Cardiovascular Disease
Human Protein C is activated by α-thrombin or α-thrombin/thrombomodulin complex to a serine protease, namely activated protein C (APC). Human Protein C can selectively inactivate factors Va and VIIIa and is a potent anticoagulant .

HY-P5062A

DEC-RVRK-CMK TFA Decanoyl-Arg-Val-Arg-Lys-chloromethylketone TFA	Furin	Infection
DEC-RVRK-CMK (Decanoyl-Arg-Val-Arg-Lys-chloromethylketone) TFA is a peptide-based CMK (chloromethylketone) inhibitor that targets and inactivates the secreted soluble kexin (Kex2) (K_i=8.45 μM). The yeast enzyme Kex2 (kexin, EC 3.4.21.61) is a calcium-dependent transmembrane protease and belongs to the mammalian protease family of the serine protease subtilisin family. The binding mechanism of Kex2 with different CMK inhibitors depends on substrate selectivity, particularly the selective differences between lysine and arginine at the P1 position .

HY-115753

Calpain Inhibitor-1	Proteasome	Neurological Disease
Calpain Inhibitor-1 (compound 36) is a potent and selective cysteine protease calpain 1 (Cal1) inhibitor (IC₅₀=100 nM; K_i=2.89 μM) .

HY-112128

USP7-IN-3 1 Publications Verification	Deubiquitinase MDM-2/p53	Cancer
USP7-IN-3 (Compound 5) is an effective and selective allosteric inhibitor of ubiquitin-specific protease 7 (USP7). USP7-IN-3 can be used for research on acute lymphoblastic leukemia .

HY-120624

BMS-354326	Ser/Thr Protease	Inflammation/Immunology
BMS-354326 is a tryptase inhibitor with an IC₅₀ of 1.8 nM. BMS-354326 exhibits excellent selectivity against trypsin and most other related serine proteases. BMS-354326 can be used in the research of asthma and inflammatory diseases .

HY-155556

ZG36	ClpP	Cancer
ZG36 is a human *Caseinolytic protease* P (ClpP*) agonist. ZG36 non-selectively* degrades respiratory chain complexes and reduces mitochondrial DNA, ultimately leading to mitochondrial dysfunction and leukemic cell death. ZG36 also inhibits the development of acute myeloid leukemia in a xenograft mouse model .

HY-145349

FXIa-IN-6	Factor Xa	Cardiovascular Disease
FXIa-IN-6 is a potent FXIa inhibitor with selectivity against most of the relevant serine proteases (K_i = 0.3 nM).

HY-P5062

DEC-RVRK-CMK Decanoyl-Arg-Val-Arg-Lys-chloromethylketone	Furin	Infection
DEC-RVRK-CMK (Decanoyl-Arg-Val-Arg-Lys-chloromethylketone) is a peptide-based CMK (chloromethylketone) inhibitor that targets and inactivates the secreted soluble kexin (Kex2) (K_i=8.45 μM). The yeast enzyme Kex2 (kexin, EC 3.4.21.61) is a calcium-dependent transmembrane protease and belongs to the mammalian protease family of the serine protease subtilisin family. The binding mechanism of Kex2 with different CMK inhibitors depends on substrate selectivity, particularly the selective differences between lysine and arginine at the P1 position .

HY-122592

Zifaxaban	Factor Xa	Cardiovascular Disease
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC₅₀ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .

HY-14853

Darexaban YM150	Factor Xa Ser/Thr Protease	Cardiovascular Disease
Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC₅₀ of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .

HY-17367S4

Atazanavir-d6 BMS-232632-d₆	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-158763

MPI8 TG0205221	SARS-CoV Cathepsin Virus Protease	Infection
MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). MPI8 can be used in clinical studies of COVID-19 .

HY-14360

MK 1256	Cathepsin	Metabolic Disease
MK 1256 is a highly selective and orally active inhibitor of tissue protease K (Cat K) with an IC₅₀ of 0.62 nM. MK 1256 shows extremely high selectivity towards other tissue proteases (all > 1100 times), with only a slightly lower selectivity for tissue protease F (Cat F) (110 times). MK 1256 exhibits strong anti-bone resorption activity in the osteoporosis model of rhesus monkeys with ovariectomy. MK 1256 can be used for research on osteoporosis .

HY-174998

HIV-1 protease-IN-15	HIV HIV Protease	Infection
HIV-1 protease-IN-15 (Compound 27) is an orally active and selective inhibitor targeting HIV-1 protease with a pIC₅₀ value of 9.347. HIV-1 protease-IN-15 inhibits HIV protein maturation, blocks viral replication. HIV-1 protease-IN-15 is promising for research of HIV-1 infection .

Cat. No.	Product Name

HY-LD004

DEL Covalent Library

14 million compounds

DEL technology enables the simultaneous screening of millions or billions of compounds in a single tube by covalently linking each small molecule with a unique DNA sequence. Traditional DEL screening primarily focuses on identifying non-covalent binding molecules, where interactions with the target are reversible. In contrast, DNA‑encoded covalent library is an ultra‑high‑throughput screening library developed on the basis of conventional DNA‑encoded library technology. It incorporates controllable electrophilic covalent warheads capable of forming irreversible covalent bonds with amino acid residues at the active sites of target proteins, including Cys, Lys, Ser, Tyr, and others. This covalent binding enhances binding affinity, prolongs residence time at the target site, and has the potential to overcome challenges associated with traditional non-covalent inhibitors, such as drug resistance or off-target effects.

Each compound in the library contains both a binding domain and an electrophilic warhead. It first recognizes and binds to the target through non covalent interactions, and then forms a stable covalent bond with key amino acid residues to achieve irreversible inhibition. This library is specifically designed for the discovery of potent, long lasting, and highly selective covalent inhibitors, particularly for undruggable targets such as kinases, GPCRs, proteases, and mutant oncoproteins. Each molecule is uniquely labeled with a DNA barcode for molecular identification and sequencing decoding.

This library is an advanced and highly diverse collection, consists of 35 independent sub-libraries with a total scaleof 14 million compounds, It incorporates over 14 experimentally validated covalent warheads capable of targeting cysteine, lysine, arginine, aspartic acid and glutamic acid. This library is constructed with diverse drug like core scaffolds and integrated controllable covalent warheads, it features structural diversity, reaction spec

Cat. No.	Product Name	Target	Research Area

HY-P0078

TRAP-6 5+ Cited Publications PAR-1 agonist peptide; Thrombin Receptor Activator Peptide 6	Protease Activated Receptor (PAR)	Inflammation/Immunology
TRAP-6 (PAR-1 agonist peptide), a peptide fragment, is a selective protease activating receptor 1 (PAR1) agonist. TRAP-6 activates human platelets via the thrombin receptor. TRAP-6 shows no activity at PAR4 .

HY-P2518

Protease-Activated Receptor-1, PAR-1 Agonist	Protease Activated Receptor (PAR)	Inflammation/Immunology
Protease-Activated Receptor-1, PAR-1 Agonist is a selective proteinase-activated receptor1 (PAR-1) agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor .

HY-P4284

Z-GGF-CMK	Proteasome ClpP Bacterial	Infection
Z-GGF-CMK is an Antibacterial agent, an inhibitor of the ClpP1P2 serine protease complex (with an IC₅₀ of 50 μM against intracellular ClpP1P2 protease activity in Mycobacterium bovis BCG), and a selective inhibitor of the mycobacterial Proteasome (with an IC₅₀ of 50 μM against the proteasome in M. bovis BCG). Z-GGF-CMK inhibits the growth of mycobacteria. Z-GGF-CMK exhibits cytotoxic activity against liver cancer cells. Z-GGF-CMK can be used in the research of tuberculosis .

HY-W790014

Z-FG-NHO-BzOME	Cathepsin	Infection
Z-FG-NHO-BzOME is a cysteine protease inhibitor that selectively inhibits cathepsin B, cathepsin L, cathepsin S, and papain .

HY-P10336

Serpinin	Serpin	Neurological Disease Endocrinology
Serpinin is an agonist of the protease inhibitor Nexin-1 (PN-1). Serpinin upregulates the expression of PN-1 through the cAMP-PKA-Sp1 signaling pathway, promoting granule biogenesis in endocrine cells. Serpinin is used in research related to the regulation of secretory function . Serpinin is a selective agonist for β-adrenergic receptors. Serpinin interacts with β1-adrenergic receptors to activate the AC-cAMP-PKA pathway, which regulates myocardial systolic and diastolic function. pGlu-serpinin upregulates Bcl2 mRNA transcription and exerts neuroprotective effects .

HY-P5062A

DEC-RVRK-CMK TFA Decanoyl-Arg-Val-Arg-Lys-chloromethylketone TFA	Furin	Infection
DEC-RVRK-CMK (Decanoyl-Arg-Val-Arg-Lys-chloromethylketone) TFA is a peptide-based CMK (chloromethylketone) inhibitor that targets and inactivates the secreted soluble kexin (Kex2) (K_i=8.45 μM). The yeast enzyme Kex2 (kexin, EC 3.4.21.61) is a calcium-dependent transmembrane protease and belongs to the mammalian protease family of the serine protease subtilisin family. The binding mechanism of Kex2 with different CMK inhibitors depends on substrate selectivity, particularly the selective differences between lysine and arginine at the P1 position .

HY-P5372A

Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA	Protease Activated Receptor (PAR)	Cancer
Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA, a bioactive peptide, is a selective Protease activating receptor 1 (PAR-1) agonist over PAR-2. PAR-1 belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type' .

HY-P5062

DEC-RVRK-CMK Decanoyl-Arg-Val-Arg-Lys-chloromethylketone	Furin	Infection
DEC-RVRK-CMK (Decanoyl-Arg-Val-Arg-Lys-chloromethylketone) is a peptide-based CMK (chloromethylketone) inhibitor that targets and inactivates the secreted soluble kexin (Kex2) (K_i=8.45 μM). The yeast enzyme Kex2 (kexin, EC 3.4.21.61) is a calcium-dependent transmembrane protease and belongs to the mammalian protease family of the serine protease subtilisin family. The binding mechanism of Kex2 with different CMK inhibitors depends on substrate selectivity, particularly the selective differences between lysine and arginine at the P1 position .

HY-W012572A

D-Histidine hydrochloride hydrate	Mitochondrial Metabolism Bacterial	Infection Metabolic Disease
D-Histidine hydrochloride hydrate is an anti-biofilm agent that targets bacterial quorum sensing systems (such as RhlI/RhlR pathway) and has antibacterial activity. D-Histidine hydrochloride hydrate works by non-covalently binding to bacterial regulatory factors or copper ion complexes, selectively inhibiting bacterial biofilm formation and motility. D-Histidine hydrochloride hydrate downregulates quorum sensing-related gene expression, reduces the synthesis of virulence factors (such as alginate and proteases), and interferes with bacterial membrane stability, inhibiting biofilm formation, promoting the disintegration of mature biofilms, and enhancing antibiotic sensitivity. D-Histidine hydrochloride hydrate is also an efficient catalyst for the salt-induced peptide formation (SIPF) reaction, which promotes the condensation of amino acids to form dipeptides (such as dialanine and dilysine) by forming a complex with copper ions (Cu ²⁺) .

HY-P5377

Abz-HPGGPQ-EDDnp Cathepsin K substrate	Ser/Thr Protease	Others
Abz-HPGGPQ-EDDnp (Cathepsin K substrate) is a biological active peptide. (Cathepsins are a class of globular lysosomal proteases, playing a vital role in mammalian cellular turnover. They degrade polypeptides and are distinguished by their substrate specificities. Cathepsin K is the lysosomal cysteine protease involved in bone remodeling and resorption. It has potential as a drug target in autoimmune diseases and osteoporosis.This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2, 4-dinitrophenyl)-ethylenediamine], a substrate initially developed for trypanosomal enzymes, is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B, F, H, L, S and V, Ex/Em=340 nm/420 nm.)

HY-P5372

Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2	Protease Activated Receptor (PAR)	Cancer
Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2, a bioactive peptide, is a selective Protease activating receptor 1 (PAR-1) agonist over PAR-2. PAR-1 belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type' .

HY-P2518A

Protease-Activated Receptor-1, PAR-1 Agonist TFA	Protease Activated Receptor (PAR)	Cancer
Protease-Activated Receptor-1, PAR-1 Agonist TFA is a selective proteinase-activated receptor1 (PAR-1) agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist TFA corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor .

HY-P5312

Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr	Virus Protease	Infection
Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr is a WNV NS2B-NS3 protease substrate. Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr is used for WNV NS2B-NS3 protease substrate peptide selective inhibitor development .

HY-P5312A

Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr acetate	Virus Protease	Infection
Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr acetate is the acetate salt form of Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr. Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr acetate is the substrate for WNV NS2B NS3 protease, which is utilized for the development of WNV protease substrate peptide selective inhibitor .

HY-P4404

Abz-GIVRAK(Dnp)	Cathepsin	Others
Abz-GIVRAK(Dnp) is the most efficient substrate for cathepsin B and is highly selective for this enzyme among lysosomal cysteine proteases. After Abz-GIVRAK(Dnp) is hydrolyzed, aminoacylbenziminosulfosuccinic acid (Abz-SAS) is released, and dinitrobenzoyl (Dnp) is also released. The product of this hydrolysis reaction, Abz-SAS, is fluorescent under ultraviolet light and can emit a fluorescent signal .

HY-P5415

DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS	HIV	Others
DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is a biological active peptide. (DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is also called HIV protease substrate I in some literature. It is widely used for the continuous assay for HIV protease activity. The 11-K_d protease (PR) encoded by the human immunodeficiency virus 1 (HIV-1) is essential for the correct processing of viral polyproteins and the maturation of infectious virus, and is therefore a target for the design of selective acquired immunodeficiency syndrome (AIDS) therapeutics. The FRET-based fluorogenic substrate is derived from a natural processing site for HIV-1 PR. Incubation of recombinant HIV-1 PR with the fluorogenic substrate resulted in specific cleavage at the Tyr-Pro bond and a time-dependent increase in fluorescence intensity that is linearly related to the extent of substrate hydrolysis. The fluorescence quantum yields of the HIV-1 PR substrate in the FRET assay increased by 40.0- and 34.4-fold, respectively, per mole of substrate cleaved. Because of its simplicity and precision in the determination of reaction rates required for kinetic analysis, this substrate offers many advantages over the commonly used HPLC or electrophoresis-based assays for peptide substrate hydrolysis by retroviral PRs. Abs/Em = 340nm/490nm.)

HY-P11420

2A/2B Dengue protease substrate	Dengue Virus	Infection
2A/2B Dengue protease substrate (Ac-RTSKKR-pNA) is a peptide substrate for Dengue NS2B-NS3 protease. 2A/2B Dengue protease substrate is used for Dengue NS2B-NS3 protease substrate peptide selective inhibitor development .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)
Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)
Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor with blood-brain barrier permeability. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-W012572

D-Histidine	Microorganisms Source Classification	Mitochondrial Metabolism Bacterial
D-Histidine is an anti-biofilm agent that targets bacterial quorum sensing systems (such as RhlI/RhlR pathway) and has antibacterial activity. D-Histidine works by non-covalently binding to bacterial regulatory factors or copper ion complexes, selectively inhibiting bacterial biofilm formation and motility. D-Histidine downregulates quorum sensing-related gene expression, reduces the synthesis of virulence factors (such as alginate and proteases), and interferes with bacterial membrane stability, inhibiting biofilm formation, promoting the disintegration of mature biofilms, and enhancing antibiotic sensitivity. D-Histidine is also an efficient catalyst for the salt-induced peptide formation (SIPF) reaction, which promotes the condensation of amino acids to form dipeptides (such as dialanine and dilysine) by forming a complex with copper ions (Cu ²⁺) .

HY-N5185

Cyclothiazomycin	Microorganisms Antibiotics Other Antibiotics Source Classification	Fungal
Cyclothiazomycin selectively inhibits renin activity and does not inhibit pepsin, aspartic acid, serine, mercaptan protease and metalloproteinases. Cyclothiazomycin has weak antifungal activity .

HY-N4333

Rivulariapeptolides 988	Natural Products Microorganisms Source Classification	Ser/Thr Protease
Rivulariapeptolides 988 is a high potent and selective serine protease inhibitor with IC₅₀ values of 95.46 nM, 15.29 nM and 85.50 nM for chymotrypsin, elastase and proteinase K, respectively .

HY-N4332

Rivulariapeptolides 1121	Natural Products Microorganisms Source Classification	Ser/Thr Protease
Rivulariapeptolides 1121 is a high potent and selective serine protease inhibitor with IC₅₀ values of 35.52 nM, 13.24 nM and 48.05 nM for chymotrypsin, elastase and proteinase K, respectively .

HY-N4331

Rivulariapeptolides 1185	Natural Products Microorganisms Source Classification	Ser/Thr Protease
Rivulariapeptolides 1185 is a high potent and selective serine protease inhibitor with IC₅₀ values of 13.17 nM, 23.59 nM and 55.26 nM for chymotrypsin, elastase and proteinase K, respectively .

HY-17367AR

Atazanavir sulfate (Standard) BMS-232632 sulfate (Standard)	Structural Classification Alkaloids Pyridine Alkaloids Endogenous metabolite Source Classification	Reference Standards HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (sulfate) (Standard) is the analytical standard of Atazanavir (sulfate). This product is intended for research and analytical applications. Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-17367R

Atazanavir (Standard) BMS-232632 (Standard)	Structural Classification Alkaloids Pyridine Alkaloids Endogenous metabolite Source Classification	Reference Standards HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-W012572R

D-Histidine (Standard)	Microorganisms Source Classification	Reference Standards Mitochondrial Metabolism Bacterial
D-Histidine (Standard) is the analytical standard of D-Histidine (HY-W012572). This product is intended for research and analytical applications. D-Histidine is an anti-biofilm agent that targets bacterial quorum sensing systems (such as RhlI/RhlR pathway) and has antibacterial activity. D-Histidine works by non-covalently binding to bacterial regulatory factors or copper ion complexes, selectively inhibiting bacterial biofilm formation and motility. D-Histidine downregulates quorum sensing-related gene expression, reduces the synthesis of virulence factors (such as alginate and proteases), and interferes with bacterial membrane stability, inhibiting biofilm formation, promoting the disintegration of mature biofilms, and enhancing antibiotic sensitivity. D-Histidine is also an efficient catalyst for the salt-induced peptide formation (SIPF) reaction, which promotes the condensation of amino acids to form dipeptides (such as dialanine and dilysine) by forming a complex with copper ions (Cu ²⁺) .

HY-N16745

5-Hydroxynoracronycine	Structural Classification Alkaloids Citrus hystrix DC. Rutaceae Acridone Alkaloids Plants Source Classification	Parasite HIV HIV Protease
5-Hydroxynoracronycine is a selective inhibitor targeting Leishmania, HIV-1 protease, and nitric oxide (NO) production. 5-Hydroxynoracronycine has an IC₅₀ of 93.1 μmol/L against HIV-1 protease and an IC₅₀ of 0.19 mg/mL for scavenging DPPH free radicals. 5-Hydroxynoracronycine exerts anti-leishmanial, anti-HIV, antioxidant and antibacterial activities by inhibiting pathogen proliferation, enzyme activity and inflammation-related NO excessive production. 5-Hydroxynoracronycine can be used in the research of leishmaniasis, HIV infection, and inflammation-related diseases .

HY-N15079

Arphamenine B	Microorganisms Antibiotics Other Antibiotics Source Classification	Bacterial
Arphamenine B is a Zn ²⁺-dependent exopeptidase that selectively removes arginine and/or lysine residues from the NH2-terminus of several peptide substrates. Arphamenine B is an inhibitor of aminopeptidase B that can be isolated from bacteria. Arphamenine B enhances the immune response and is used to characterize novel proteases .

HY-N16719

Picrasidine J	Structural Classification Alkaloids Simaroubaceae Plants Picrasma quassioides(D．Don)Benn． Indole Alkaloids Source Classification	Kallikrein ERK Cadherin β-catenin
Picrasidine J is a selective inhibitor targeting the KLK-10 protease and the ERK signaling pathway. Picrasidine J inhibits epithelial-mesenchymal transition (EMT) by upregulating E-Cadherin and ZO-1 and downregulating β-catenin and Snail, while simultaneously reducing KLK-10 expression and inhibiting ERK phosphorylation, thereby exhibiting significant anti-migratory and anti-invasive activity. Picrasidine J can inhibit the metastasis of head and neck squamous cell carcinoma (HNSCC) and is primarily used in anti-metastasis research for head and neck tumors .

Cat. No.	Product Name	Chemical Structure

HY-17367S4

Atazanavir-d6
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-17367S2

Atazanavir-d9

Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-14588S1

Lopinavir-d8

Lopinavir-d₈ (ABT-378-d₈) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 14.2 μM .

HY-17367S

Atazanavir-d15
Atazanavir-d15 is the d₁₅ labled Atazanavir (HY-17367). Atazanavir is a selective HIV-1 protease inhibitor .

HY-17367S1

Atazanavir-d18
Atazanavir-d18 is the d₁₈ labled Atazanavir (HY-17367). Atazanavir is a selective HIV-1 protease inhibitor .

HY-17367S3

Atazanavir-d5

Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-14588S2

Lopinavir-d7

Lopinavir-d₇ is deuterated labeled Lopinavir (HY-14588). Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-14588S

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈) is the deuterium labeled Lopinavir (HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .

HY-10119S

Vorapaxar-d5
Vorapaxar-d₅ is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-106161S1

Rupintrivir-d7
Rupintrivir-d7 is a deuterated labeled Rupintrivir . Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC₅₀ of 0.023 μM. Rupintrivirvr shows immune-modulatory effect .

HY-B0689S1

Indinavir-13C4,15N

Indinavir- ¹³C₄, ¹⁵N (MK-639 (free base)- ¹³C₄, ¹⁵N) is ¹³C and ¹⁵N labeled Indinavir. Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CL ^pro inhibitor .

HY-17367S5

Atazanavir-d24

Atazanavir-d₂₄ (BMS-232632-d₂₄) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

Cat. No.	Product Name		Classification

HY-D2342

SARS-CoV-2 3CLpro probe-1		Alkynes
SARS-CoV-2 3CLpro probe-1 (Compound probe 3) is a selective and activity-based probe for the SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro probe-1 can detect endogenously expressed 3CLpro in SARS-CoV-2-infected cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks